Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology

European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…

Read More

Perioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?

Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…

Read More

Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma

Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…

Read More

Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma

Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…

Read More

New Immunohistochemical Markers for Pleural Mesothelioma Subtyping

Diagnostics 2023 September 14 [Link] Iosè Di Stefano, Greta Alì, Anello Marcello Poma, Rossella Bruno, Agnese Proietti, Cristina Niccoli, Carmelina Cristina Zirafa, Franca Melfi, Maria Giovanna Mastromarino, Marco Lucchi, Gabriella Fontanini Abstract Pleural mesothelioma (PM) comprises three main subtypes: epithelioid, biphasic and sarcomatoid, which have different impacts on prognosis and treatment definition. However, PM subtyping…

Read More

Malignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data

Artificial Intelligence in Medicine 2023 September [Link] Mark Eastwood, Silviu Tudor Marc, Xiaohong Gao, Heba Sailem, Judith Offman, Emmanouil Karteris, Angeles Montero Fernandez, Danny Jonigk, William Cookson, Miriam Moffatt, Sanjay Popat, Fayyaz Minhas, Jan Lukas Robertus Abstract Malignant Mesothelioma is a difficult to diagnose and highly lethal cancer usually associated with asbestos exposure. It can…

Read More

Extrathoracic Metastases in Pleural Mesothelioma

JTO Clinical and Research Reports 2023 August 2 [Link] Ibiayi Dagogo-Jack, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy Abstract Introduction: Guidelines recommend obtaining a computed tomography scan of the chest for the staging of pleural mesothelioma and for assessing response to treatment. Consensus is lacking regarding the necessity of serial imaging of distant extrathoracic…

Read More

Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy

Molecular Cancer 2023 July 17 [Link] F Torricelli, B Donati, F Reggiani, V Manicardi, S Piana, R Valli, F Lococo, Alessia Ciarrocchi Abstract Background: Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping the classical genetic model of cancer evolution and characterized by wide heterogeneity and transcriptional plasticity. Clinical evolution of MPM is marked by…

Read More

Management of sarcomatoid Malignant pleural mesothelioma brain metastases with stereotactic radiosurgery: an Illustrative case

British Journal of Neurosurgery 2023 July 9 [Link] Jack K Donohue, Zhishuo Wei, Hansen Deng, Ajay Niranjan, L Dade Lunsford Abstract Background: Malignant pleural mesothelioma (MPM) is a rare cancer of the respiratory system that rarely metastasizes to the brain. We report a case of sarcomatoid MPM (SMPM) managed with Stereotactic radiosurgery (SRS) to achieve…

Read More

Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma

Cytopathology 2023 June 19 [Link] Mohammed S I Mansour, Adela Huseinzade, Tomas Seidal, Kim Hejny, Athar Maty, Fereshteh Taheri-Eilagh, Ulrich Mager, Annika Dejmek, Katalin Dobra, Hans Brunnström Abstract Objective: Traditionally, the diagnosis of pleural mesothelioma is based on histological material. Minimally invasive effusion cytology specimens are an alternative that, like biopsies, require ancillary analyses. Validation…

Read More